COVID-19 Vaccine Effectiveness Among Health Workers in Georgia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-20

Study Completion Date

2022-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective one-year cohort study of hospital-based health workers in Georgia to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection and COVID-19 disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acceptability of a COVID-19 Vaccine Among US Adults Over Two Time Periods

NCT04703790

Covid19 Vaccine Acceptability

COMPLETED

Expectations About the COVID-19 Vaccines

NCT04928911

Vaccine Adverse Reaction

COMPLETED

Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers

NCT04666012

COVID-19

COMPLETED PHASE1/PHASE2

Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers

NCT04795414

SARS-CoV-2 Infection Covid19

UNKNOWN

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19

NCT04922788

SARS-CoV-2 Infection COVID-19

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.

This is a prospective one-year cohort study of hospital-based health workers in Georgia to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection and COVID-19 disease. Health Workers (HWs) are the target population in this study because they have been prioritized to be the first group to receive the vaccine in Georgia and offer an early opportunity to evaluate the vaccine in a population in which it is critical that an effective vaccine be deployed.

HWs should be enrolled after the study protocol is approved by the local ethical review committee. All HWs eligible to be vaccinated with COVID-19 vaccine can be enrolled in the study, including those who intend to get vaccinated, those who do not plan on getting vaccinated, and those who are not sure. For HWs who have already been vaccinated at enrolment, priority will be given to those who have received their first COVID vaccine no more than 4 days prior to the date of enrolment. The target enrolment is 1600 participants.

At enrolment, study participants will complete a baseline enrolment survey about demographics, clinical comorbidities, and work and community-related behaviors related to infection risk, and recent symptoms. In addition, a baseline serology will be collected from participants at enrolment.

For study participants who have not received their first COVID-19 vaccine at enrolment but receive their first vaccine 14 days or more after enrolment, an additional blood sample will be collected. In addition, a brief symptom questionnaire about recent symptoms will be administered.

During the course of the study, participants will be actively followed for suspected COVID-19 infection. Participants will be asked to complete weekly symptom questionnaires to screen for clinically significant COVID-19. Participants who meet a suspected case definition, defined according to the Georgian national case definition should provide a respiratory sample which will be collected by trained HW. Respiratory specimens will be tested for SARS-CoV-2 by RT-PCR.

All or subset of positive samples from study participants will undergo genetic sequencing, resources permitting.

Finally, after 3, 6, 9 and 12 months of the study, as resources permit, serology will be collected from participants. Serology will be tested for antibodies to SARS-CoV-2 by tests for vaccine-induced antibodies and antibodies that result from natural infection.

Vaccine effectiveness should be analysed as described in the analysis section below.

In addition to the final analysis at the end of the one-year period, interim quarterly (every three months) analyses will be undertaken.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccinated participants

Participants who received 1or 2 doses of the Covid-19 vaccines

Covid-19 vaccines

Intervention Type BIOLOGICAL

Observation of individuals who received one or more doses of covid-19 vaccines.

Unvaccinated participants

Participants who have not received any dose of the Covid-19 vaccines

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Covid-19 vaccines

Observation of individuals who received one or more doses of covid-19 vaccines.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All HWs eligible to receive the COVID-19 vaccination according to the national guidelines of Ministry of Health (MoH).

* HWs working at Batumi Republican Clinical Hospital, Vakhtang Bochorishvili Clinic, Academician N. Kipshidze Central University Clinic, Bokeria Tbilisi Referral Hospital, Caucasus Medical Centre, and Infectious Diseases and AIDS Center.
* HWs who have already been vaccinated with a single dose of vaccine against COVID-19 as part of the early COVID-19 vaccine rollout can be included.

Exclusion Criteria

* HWs who are not eligible for COVID-19 vaccination or have a contraindication to vaccination should not participate in the study.
* HWs who do not work at above mentioned hospitals
* HWs under 18 years of age.
* HWs who have already been vaccinated with two doses of vaccine against COVID-19 before enrolment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes